Needham & Company LLC restated their buy rating on shares of Vir Biotechnology (NASDAQ:VIR - Free Report) in a report released on Friday, Benzinga reports. They currently have a $19.00 target price on the stock.
Several other research analysts also recently weighed in on VIR. HC Wainwright reissued a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Tuesday, August 20th. Barclays upped their target price on shares of Vir Biotechnology from $27.00 to $28.00 and gave the company an "overweight" rating in a report on Friday, August 2nd. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $36.80.
Get Our Latest Report on Vir Biotechnology
Vir Biotechnology Stock Performance
VIR stock traded up $1.77 during midday trading on Friday, hitting $9.26. 7,286,093 shares of the stock were exchanged, compared to its average volume of 1,021,971. The stock's 50-day moving average price is $7.74 and its 200-day moving average price is $8.86. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -2.30 and a beta of 0.46. Vir Biotechnology has a fifty-two week low of $7.12 and a fifty-two week high of $13.09.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.60). The firm had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. Vir Biotechnology had a negative return on equity of 30.93% and a negative net margin of 612.40%. The business's revenue for the quarter was down 9.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.22) earnings per share. Research analysts anticipate that Vir Biotechnology will post -3.26 EPS for the current year.
Insider Activity
In other news, Director Janet Napolitano sold 12,190 shares of the company's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $7.80, for a total transaction of $95,082.00. Following the completion of the transaction, the director now owns 11,616 shares of the company's stock, valued at $90,604.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 15.60% of the company's stock.
Institutional Trading of Vir Biotechnology
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Texas Permanent School Fund Corp increased its position in Vir Biotechnology by 1.4% during the 1st quarter. Texas Permanent School Fund Corp now owns 74,977 shares of the company's stock worth $760,000 after purchasing an additional 1,012 shares in the last quarter. Louisiana State Employees Retirement System grew its position in Vir Biotechnology by 2.8% in the second quarter. Louisiana State Employees Retirement System now owns 43,800 shares of the company's stock valued at $390,000 after acquiring an additional 1,200 shares in the last quarter. PNC Financial Services Group Inc. grew its position in Vir Biotechnology by 20.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 11,186 shares of the company's stock valued at $113,000 after acquiring an additional 1,869 shares in the last quarter. ProShare Advisors LLC grew its position in Vir Biotechnology by 8.4% in the first quarter. ProShare Advisors LLC now owns 26,392 shares of the company's stock valued at $267,000 after acquiring an additional 2,035 shares in the last quarter. Finally, Blue Trust Inc. grew its position in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company's stock valued at $30,000 after acquiring an additional 2,351 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company's stock.
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
See Also
Before you consider Vir Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.
While Vir Biotechnology currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
